Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant < em > Enterobacteriaceae < /em >
Expert Rev Anti Infect Ther. 2022 Jan 15. doi: 10.1080/14787210.2022.2030219. Online ahead of print.ABSTRACTINTRODUCTION: The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin and colistin.AREAS COVERED: The search terms "meropenem-vaborbactam" or RX7009 for the years 2006 until 2021 were used.EXPERT OPINION: Coupling of meropenem with the cyclic boronate derivative varobactam enhances considerably the in vitro intrinsic activity of meropenem against isolates producin...
Source: Expert Review of Anti-Infective Therapy - January 17, 2022 Category: Infectious Diseases Authors: Maria Mouktaroudi Antigone Kotsaki Evangelos J Giamarellos-Bourboulis Source Type: research

A systems thinking approach for antimicrobial stewardship in primary care
Expert Rev Anti Infect Ther. 2021 Dec 30:1-9. doi: 10.1080/14787210.2022.2023010. Online ahead of print.ABSTRACTINTRODUCTION: The establishment of antimicrobial stewardship (AMS) in primary care is central to substantially reduce the antimicrobial use and the associated risk of resistance. This perspective piece highlights the importance of systems thinking to set up and facilitate AMS programs in primary care.AREAS COVERED: The challenges that primary care faces to incorporate AMS programmes is multifactorial: an implementation framework, relevant resources, team composition, and system structures remain under-researched,...
Source: Expert Review of Anti-Infective Therapy - December 30, 2021 Category: Infectious Diseases Authors: Sajal K Saha David C M Kong Danielle Mazza Karin Thursky Source Type: research

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
Expert Rev Anti Infect Ther. 2021 Dec 23. doi: 10.1080/14787210.2022.2020099. Online ahead of print.ABSTRACTINTRODUCTION: Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the fight against carbapenem-resistant (CR) Gram-negative infections. Some recently approved antibiotics and older generic antibiotics with activity against CR Gram-negative bacteria were investigated in PF-RCTs in a variety of infections.AREAS COVERED: We searched Pubmed, Cochrane database and international clinical trial databases for PF-RCTs for the period between 2005 and 2020 and compared the study designs, patient population...
Source: Expert Review of Anti-Infective Therapy - December 23, 2021 Category: Infectious Diseases Authors: Thomas P Lodise Matteo Bassetti Ricard Ferrer Thierry Naas Yoshihito Niki David L Paterson Markus Zeitlinger Roger Echols Source Type: research

Multicenter surveillance of < em > in vitro < /em > activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against < em > Enterobacterales, Pseudomonas aeruginosa < /em > , and < em > Acinetobacter baumannii < /em > complex causing bloodstream infection in Taiwan, 2020
CONCLUSIONS: : The efficacy of novel antibiotics against important drug-resistant GNB must be monitored and validated during the clinical treatment of patients.PMID:34933656 | DOI:10.1080/14787210.2022.2021876 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 22, 2021 Category: Infectious Diseases Authors: Shio-Shin Jean Wen-Chien Ko Wen-Sen Lee Min-Chi Lu Po-Ren Hsueh SMART Program Source Type: research

Therapeutic potential of 5-aminolevulinic acid and sodium-ferrous citrate for viral insults: relevance to the COVID-19 crisis
Expert Rev Anti Infect Ther. 2021 Dec 20. doi: 10.1080/14787210.2022.2020097. Online ahead of print.ABSTRACTINTRODUCTION: : 5-Aminolevulinic acid (5-ALA) is a naturally synthesized amino acid present in most plants as well as animals, and it is routinely consumed by humans. This brief report sought to describe the potential of 5-ALA and sodium-ferrous citrate (5-ALA/SFC) to ameliorate the course of coronavirus disease 2019 (COVID-19).AREAS COVERED: : Studies have shown that 5-ALA is converted to protoporphyrin IX (PPIX), then to heme. Recent studies have demonstrated that PPIX has antiviral effects against several viruses,...
Source: Expert Review of Anti-Infective Therapy - December 20, 2021 Category: Infectious Diseases Authors: Hideyuki Negoro Christos Chatziantonio Mohammed S Razzaque Source Type: research

Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia
Expert Rev Anti Infect Ther. 2021 Dec 16. doi: 10.1080/14787210.2021.2020098. Online ahead of print.ABSTRACTINTRODUCTION: Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones.AREAS COVERED: The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-acquired bacterial pneumonia (CABP).EXPERT OPINION: Delafloxacin is novel fluoroquinolone with a unique pr...
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Matteo Bassetti Monica Melchio Daniele Roberto Giacobbe Source Type: research

Single ascending dose safety, tolerability and pharmacokinetic study of econazole in healthy volunteers
CONCLUSION: Based on the findings of our study, a dose of 500mg Econazole, once a day orally was considered as appropriate for further evaluation.PMID:34913825 | DOI:10.1080/14787210.2022.2016392 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Himanshi Khera Avaneesh Kumar Pandey Nusrat Shafiq G K Khuller Ritika Kondel Bhandari Aditi Panditrao Nanda Gamad Rachna Rohilla Samiksha Bhattacharjee Naveen Murali Harish Cvn Devraj Belavagi Chakrant Mothsara Manjula Singh Navneet Sharma Digamber Behera Source Type: research

Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia
Expert Rev Anti Infect Ther. 2021 Dec 16. doi: 10.1080/14787210.2021.2020098. Online ahead of print.ABSTRACTINTRODUCTION: Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones.AREAS COVERED: The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-acquired bacterial pneumonia (CABP).EXPERT OPINION: Delafloxacin is novel fluoroquinolone with a unique pr...
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Matteo Bassetti Monica Melchio Daniele Roberto Giacobbe Source Type: research

Single ascending dose safety, tolerability and pharmacokinetic study of econazole in healthy volunteers
CONCLUSION: Based on the findings of our study, a dose of 500mg Econazole, once a day orally was considered as appropriate for further evaluation.PMID:34913825 | DOI:10.1080/14787210.2022.2016392 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Himanshi Khera Avaneesh Kumar Pandey Nusrat Shafiq G K Khuller Ritika Kondel Bhandari Aditi Panditrao Nanda Gamad Rachna Rohilla Samiksha Bhattacharjee Naveen Murali Harish Cvn Devraj Belavagi Chakrant Mothsara Manjula Singh Navneet Sharma Digamber Behera Source Type: research

Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia
Expert Rev Anti Infect Ther. 2021 Dec 16. doi: 10.1080/14787210.2021.2020098. Online ahead of print.ABSTRACTINTRODUCTION: Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones.AREAS COVERED: The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-acquired bacterial pneumonia (CABP).EXPERT OPINION: Delafloxacin is novel fluoroquinolone with a unique pr...
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Matteo Bassetti Monica Melchio Daniele Roberto Giacobbe Source Type: research

Single ascending dose safety, tolerability and pharmacokinetic study of econazole in healthy volunteers
CONCLUSION: Based on the findings of our study, a dose of 500mg Econazole, once a day orally was considered as appropriate for further evaluation.PMID:34913825 | DOI:10.1080/14787210.2022.2016392 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Himanshi Khera Avaneesh Kumar Pandey Nusrat Shafiq G K Khuller Ritika Kondel Bhandari Aditi Panditrao Nanda Gamad Rachna Rohilla Samiksha Bhattacharjee Naveen Murali Harish Cvn Devraj Belavagi Chakrant Mothsara Manjula Singh Navneet Sharma Digamber Behera Source Type: research

Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia
Expert Rev Anti Infect Ther. 2021 Dec 16. doi: 10.1080/14787210.2021.2020098. Online ahead of print.ABSTRACTINTRODUCTION: Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones.AREAS COVERED: The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-acquired bacterial pneumonia (CABP).EXPERT OPINION: Delafloxacin is novel fluoroquinolone with a unique pr...
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Matteo Bassetti Monica Melchio Daniele Roberto Giacobbe Source Type: research

Single ascending dose safety, tolerability and pharmacokinetic study of econazole in healthy volunteers
CONCLUSION: Based on the findings of our study, a dose of 500mg Econazole, once a day orally was considered as appropriate for further evaluation.PMID:34913825 | DOI:10.1080/14787210.2022.2016392 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 16, 2021 Category: Infectious Diseases Authors: Himanshi Khera Avaneesh Kumar Pandey Nusrat Shafiq G K Khuller Ritika Kondel Bhandari Aditi Panditrao Nanda Gamad Rachna Rohilla Samiksha Bhattacharjee Naveen Murali Harish Cvn Devraj Belavagi Chakrant Mothsara Manjula Singh Navneet Sharma Digamber Behera Source Type: research

Ivermectin: a pathway out of the pandemic or another dead end?
Expert Rev Anti Infect Ther. 2021 Dec 13:1-3. doi: 10.1080/14787210.2022.2012154. Online ahead of print.NO ABSTRACTPMID:34894986 | DOI:10.1080/14787210.2022.2012154 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Daniel Echeverr ía-Esnal Santiago Grau Source Type: research

Antimicrobial consumption in patients with COVID-19: A systematic review and meta-analysis
Expert Rev Anti Infect Ther. 2021 Dec 13. doi: 10.1080/14787210.2022.2011719. Online ahead of print.ABSTRACTINTRODUCTION: : Since the onset of the pandemic, prescribing antimicrobials has become a common practice to treat patients infected with COVID-19.AREAS COVERED: : A systematic literature search was performed in the electronic databases MEDLINE, CINAHL, WHO COVID-19 database, including EMBASE, Scopus, WHO-COVID, LILACS, and Google Scholar to identify original articles published up to July 31, 2021. A random-effects model was used to estimate the pooled prevalence or proportion of antimicrobial consumption among COVID-...
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Sidra Khan Syed Shahzad Hasan Stuart E Bond Barbara R Conway Mamoon A Aldayeb Source Type: research

Mitigation of insufficient hospital workforce and personal protective equipment in the anti-COVID-19 campaign in mainland China
Expert Rev Anti Infect Ther. 2021 Dec 13. doi: 10.1080/14787210.2022.2017279. Online ahead of print.NO ABSTRACTPMID:34895011 | DOI:10.1080/14787210.2022.2017279 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Qiang Huo Zhenzhen Chen Xiaojian Ren Wenqiang Chen Jun Li Source Type: research

Ivermectin: a pathway out of the pandemic or another dead end?
Expert Rev Anti Infect Ther. 2021 Dec 13:1-3. doi: 10.1080/14787210.2022.2012154. Online ahead of print.NO ABSTRACTPMID:34894986 | DOI:10.1080/14787210.2022.2012154 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Daniel Echeverr ía-Esnal Santiago Grau Source Type: research

Antimicrobial consumption in patients with COVID-19: A systematic review and meta-analysis
Expert Rev Anti Infect Ther. 2021 Dec 13. doi: 10.1080/14787210.2022.2011719. Online ahead of print.ABSTRACTINTRODUCTION: : Since the onset of the pandemic, prescribing antimicrobials has become a common practice to treat patients infected with COVID-19.AREAS COVERED: : A systematic literature search was performed in the electronic databases MEDLINE, CINAHL, WHO COVID-19 database, including EMBASE, Scopus, WHO-COVID, LILACS, and Google Scholar to identify original articles published up to July 31, 2021. A random-effects model was used to estimate the pooled prevalence or proportion of antimicrobial consumption among COVID-...
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Sidra Khan Syed Shahzad Hasan Stuart E Bond Barbara R Conway Mamoon A Aldayeb Source Type: research

Mitigation of insufficient hospital workforce and personal protective equipment in the anti-COVID-19 campaign in mainland China
Expert Rev Anti Infect Ther. 2021 Dec 13. doi: 10.1080/14787210.2022.2017279. Online ahead of print.NO ABSTRACTPMID:34895011 | DOI:10.1080/14787210.2022.2017279 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Qiang Huo Zhenzhen Chen Xiaojian Ren Wenqiang Chen Jun Li Source Type: research

Ivermectin: a pathway out of the pandemic or another dead end?
Expert Rev Anti Infect Ther. 2021 Dec 13:1-3. doi: 10.1080/14787210.2022.2012154. Online ahead of print.NO ABSTRACTPMID:34894986 | DOI:10.1080/14787210.2022.2012154 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Daniel Echeverr ía-Esnal Santiago Grau Source Type: research

Antimicrobial consumption in patients with COVID-19: A systematic review and meta-analysis
Expert Rev Anti Infect Ther. 2021 Dec 13. doi: 10.1080/14787210.2022.2011719. Online ahead of print.ABSTRACTINTRODUCTION: : Since the onset of the pandemic, prescribing antimicrobials has become a common practice to treat patients infected with COVID-19.AREAS COVERED: : A systematic literature search was performed in the electronic databases MEDLINE, CINAHL, WHO COVID-19 database, including EMBASE, Scopus, WHO-COVID, LILACS, and Google Scholar to identify original articles published up to July 31, 2021. A random-effects model was used to estimate the pooled prevalence or proportion of antimicrobial consumption among COVID-...
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Sidra Khan Syed Shahzad Hasan Stuart E Bond Barbara R Conway Mamoon A Aldayeb Source Type: research

Mitigation of insufficient hospital workforce and personal protective equipment in the anti-COVID-19 campaign in mainland China
Expert Rev Anti Infect Ther. 2021 Dec 13. doi: 10.1080/14787210.2022.2017279. Online ahead of print.NO ABSTRACTPMID:34895011 | DOI:10.1080/14787210.2022.2017279 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 13, 2021 Category: Infectious Diseases Authors: Qiang Huo Zhenzhen Chen Xiaojian Ren Wenqiang Chen Jun Li Source Type: research

Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age
In this report, we review the micafungin use in infants younger than 4 months of age. Animal studies as well as clinical data that support its use in neonatal candidiasis are reviewed. In addition, the status of FDA approval and the rationale of micafungin dosing recommendations in infants
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Nahed Abdel-Haq Stephanie M Smith Basim I Asmar Source Type: research

Comparison of tailored < em > Helicobacter pylori < /em > eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial
CONCLUSION: PAM-B therapy exhibits similar efficacy and improved cost-effectiveness compared to TT based on the results of DPO-PCR tests.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05002595.PMID:34883037 | DOI:10.1080/14787210.2022.2017280 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Jun-Hyung Cho So-Young Jin Suyeon Park Source Type: research

Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age
In this report, we review the micafungin use in infants younger than 4 months of age. Animal studies as well as clinical data that support its use in neonatal candidiasis are reviewed. In addition, the status of FDA approval and the rationale of micafungin dosing recommendations in infants
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Nahed Abdel-Haq Stephanie M Smith Basim I Asmar Source Type: research

Comparison of tailored < em > Helicobacter pylori < /em > eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial
CONCLUSION: PAM-B therapy exhibits similar efficacy and improved cost-effectiveness compared to TT based on the results of DPO-PCR tests.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05002595.PMID:34883037 | DOI:10.1080/14787210.2022.2017280 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Jun-Hyung Cho So-Young Jin Suyeon Park Source Type: research

Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age
In this report, we review the micafungin use in infants younger than 4 months of age. Animal studies as well as clinical data that support its use in neonatal candidiasis are reviewed. In addition, the status of FDA approval and the rationale of micafungin dosing recommendations in infants
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Nahed Abdel-Haq Stephanie M Smith Basim I Asmar Source Type: research

Comparison of tailored < em > Helicobacter pylori < /em > eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial
CONCLUSION: PAM-B therapy exhibits similar efficacy and improved cost-effectiveness compared to TT based on the results of DPO-PCR tests.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05002595.PMID:34883037 | DOI:10.1080/14787210.2022.2017280 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Jun-Hyung Cho So-Young Jin Suyeon Park Source Type: research

Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age
In this report, we review the micafungin use in infants younger than 4 months of age. Animal studies as well as clinical data that support its use in neonatal candidiasis are reviewed. In addition, the status of FDA approval and the rationale of micafungin dosing recommendations in infants
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Nahed Abdel-Haq Stephanie M Smith Basim I Asmar Source Type: research

Comparison of tailored < em > Helicobacter pylori < /em > eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial
CONCLUSION: PAM-B therapy exhibits similar efficacy and improved cost-effectiveness compared to TT based on the results of DPO-PCR tests.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05002595.PMID:34883037 | DOI:10.1080/14787210.2022.2017280 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - December 9, 2021 Category: Infectious Diseases Authors: Jun-Hyung Cho So-Young Jin Suyeon Park Source Type: research

Multidrug-resistant < em > Acinetobacter baumannii < /em > infections: looming threat in the Indian clinical setting
Expert Rev Anti Infect Ther. 2021 Dec 8. doi: 10.1080/14787210.2022.2016393. Online ahead of print.ABSTRACTINTRODUCTION: The recent increase in multidrug-resistant strains of A. baumannii has increased the incidences of ventilator-associated pneumoniae, catheter-associated urinary tract infections and central line- associated blood stream infections, together increasing hospital stay, treatment cost and mortality. Resistance genes blaOXA and blaNDM are dominant in India. Carbapenem-resistant A. baumannii (CRAB) International clone-2 (IC-2) are rising in India. High dependency on carbapenems and last-resort combination of t...
Source: Expert Review of Anti-Infective Therapy - December 8, 2021 Category: Infectious Diseases Authors: Prashant Chandra Rajesh V Surulivel Rajan M Shastry Cs Unnikrishnan Mk Source Type: research